Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy.

[1]  J. Cavenagh,et al.  Guidelines on the diagnosis and management of AL amyloidosis , 2004 .

[2]  R. Wiesner,et al.  Outcome of liver transplantation for familial amyloidotic polyneuropathy , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[3]  Giampaolo Merlini,et al.  Molecular mechanisms of amyloidosis. , 2003, The New England journal of medicine.

[4]  A. Movahed,et al.  Uptake of technetium 99m HDP in cardiac amyloidosis , 2003, The International Journal of Cardiovascular Imaging.

[5]  O. Leone,et al.  Combined heart and liver transplantation for familial amyloidotic polyneuropathy. , 2003, The Journal of thoracic and cardiovascular surgery.

[6]  R. Strasser,et al.  Images in cardiovascular medicine. Restrictive cardiomyopathy in familial amyloidosis TTR-Arg-50. , 2003, Circulation.

[7]  B. Hesse,et al.  99mTc-aprotinin scintigraphy in amyloidosis. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  P. Hawkins,et al.  Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis , 2002, Current opinion in nephrology and hypertension.

[9]  M. M. Saraiva.  Sporadic cases of hereditary systemic amyloidosis. , 2002, The New England journal of medicine.

[10]  D. Booth,et al.  Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. , 2002, The New England journal of medicine.

[11]  R. Linke,et al.  99mTc-DPD scintigraphy in transthyretin-related familial amyloidotic polyneuropathy , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  E. Vardareli,et al.  Myocardial Tc-99m MDP uptake on a bone scan in senile systemic amyloidosis with cardiac involvement. , 2000, Clinical nuclear medicine.

[13]  K. Kubo,et al.  Comparison of electrocardiographic findings in patients with AL (primary) amyloidosis and in familial amyloid polyneuropathy and anginal pain and their relation to histopathologic findings. , 2000, The American journal of cardiology.

[14]  P. Nihoyannopoulos,et al.  Comparison of usefulness between exercise capacity and echocardiographic indexes of left ventricular function in cardiac amyloidosis. , 1999, The American journal of cardiology.

[15]  R. Nour,et al.  Tc-99m HDP uptake in cardiac amyloidosis. , 1999, Clinical nuclear medicine.

[16]  R. Falk,et al.  The systemic amyloidoses. , 1997, The New England journal of medicine.

[17]  R. Falk,et al.  Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. , 1997, Heart.

[18]  W. Edwards,et al.  The premortem recognition of systemic senile amyloidosis with cardiac involvement. , 1996 .

[19]  E. Besada,et al.  Soft-tissue uptake of Tc-99m DPD (dicarboxypropane diphosphonate) in amyloidosis. , 1996, Clinical nuclear medicine.

[20]  G. Merlini,et al.  Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin , 1995, European Journal of Nuclear Medicine.

[21]  G. Grimon,et al.  Usefulness of technetium-99m pyrophosphate myocardial scintigraphy in amyloid polyneuropathy and correlation with echocardiography. , 1993, The American journal of cardiology.

[22]  B. Lentle,et al.  Uptake of technetium-99m MDP in primary amyloidosis with a review of the mechanisms of soft tissue localization of bone seeking radiopharmaceuticals. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  F. Salvi,et al.  Molecular strategies in genetic diagnosis of transthyretin‐related hereditary amyloidosis , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  M. Pepys,et al.  Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. , 1990, The New England journal of medicine.

[25]  M. H. Rijswijk,et al.  Soft-tissue uptake of99m-Tc-diphosphonate and99mTc-pyrophosphate in amyloidosis , 1990, European Journal of Nuclear Medicine.

[26]  D. Piers,et al.  Soft-tissue uptake of tc-99m-diphosphonate and tc-99m-pyrophosphate in amyloidosis , 1990 .

[27]  S. Ikeda,et al.  Early identification of amyloid heart disease by technetium-99m-pyrophosphate scintigraphy: a study with familial amyloid polyneuropathy. , 1987, American heart journal.

[28]  R. Falk,et al.  Cardiac technetium-99m pyrophosphate scintigraphy in familial amyloidosis. , 1984, The American journal of cardiology.

[29]  P. Eriksson,et al.  Non-invasive assessment of the presence and severity of cardiac amyloidosis. A study in familial amyloidosis with polyneuropathy by cross sectional echocardiography and technetium-99m pyrophosphate scintigraphy. , 1984, British heart journal.

[30]  R. Falk,et al.  Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis. , 1983, The American journal of cardiology.

[31]  Y. Sohn,et al.  Value of positive myocardial technetium-99m-pyrophosphate scintigraphy in the noninvasive diagnosis of cardiac amyloidosis. , 1982, American heart journal.

[32]  M. Skinner,et al.  Soft tissue uptake of bone seeking radionuclide in amyloidosis. , 1981, The Journal of rheumatology.

[33]  L. Lovat,et al.  Amyloidosis and the liver. , 1999, Journal of hepatology.

[34]  W. Edwards,et al.  Amyloidosis and endomyocardial biopsy: Correlation of extent and pattern of deposition with amyloid immunophenotype in 100 cases. , 1995, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[35]  J. Willerson,et al.  Pathophysiologic considerations and clinicopathological correlates of technetium-99m stannous pyrophosphate myocardial scintigraphy. , 1980, Seminars in nuclear medicine.